AP2008004537A0 - Muscarinic receptor antagonists - Google Patents

Muscarinic receptor antagonists

Info

Publication number
AP2008004537A0
AP2008004537A0 AP2008004537A AP2008004537A AP2008004537A0 AP 2008004537 A0 AP2008004537 A0 AP 2008004537A0 AP 2008004537 A AP2008004537 A AP 2008004537A AP 2008004537 A AP2008004537 A AP 2008004537A AP 2008004537 A0 AP2008004537 A0 AP 2008004537A0
Authority
AP
ARIPO
Prior art keywords
receptor antagonists
muscarinic receptor
muscarinic
antagonists
receptor
Prior art date
Application number
AP2008004537A
Other languages
English (en)
Inventor
Anita Chugh
Naresh Kumar
Suman Gupta
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of AP2008004537A0 publication Critical patent/AP2008004537A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2008004537A 2005-12-30 2006-12-21 Muscarinic receptor antagonists AP2008004537A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3521DE2005 2005-12-30
IN1557DE2006 2006-07-03
PCT/IB2006/055010 WO2007077510A2 (fr) 2005-12-30 2006-12-21 Antagonistes des récepteurs muscariniques

Publications (1)

Publication Number Publication Date
AP2008004537A0 true AP2008004537A0 (en) 2008-08-31

Family

ID=38038504

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004537A AP2008004537A0 (en) 2005-12-30 2006-12-21 Muscarinic receptor antagonists

Country Status (10)

Country Link
US (1) US20100222393A1 (fr)
EP (1) EP1968945A2 (fr)
JP (1) JP2009522246A (fr)
KR (1) KR20080089461A (fr)
AP (1) AP2008004537A0 (fr)
AU (1) AU2006334107A1 (fr)
BR (1) BRPI0620844A2 (fr)
CA (1) CA2635335A1 (fr)
EA (1) EA200801591A1 (fr)
WO (1) WO2007077510A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471115B1 (en) 1990-02-19 2002-10-29 Hitachi, Ltd. Process for manufacturing electronic circuit devices
US6227436B1 (en) 1990-02-19 2001-05-08 Hitachi, Ltd. Method of fabricating an electronic circuit device and apparatus for performing the method
EP2111861A1 (fr) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
KR101290893B1 (ko) 2009-04-09 2013-07-29 노파르티스 아게 피롤리디늄 염의 제조 방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953565A (en) * 1956-12-13 1960-09-20 Sahyun Melville Pyrimidyl, imidazolyl and diazepinyl acetals and glycolates
DK534178A (da) * 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
JPS55100338A (en) * 1979-01-23 1980-07-31 Sumitomo Chem Co Ltd New carboxylic acid ester, their preparation and insecticide and miticide containing the same
EP0117462A3 (fr) * 1983-02-28 1986-08-20 American Cyanamid Company N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides
NL8301550A (nl) * 1983-05-03 1984-12-03 Gist Brocades Nv Imidazolethanol esters.
DE4314407A1 (de) * 1993-05-03 1994-11-10 Zuckerindustrie Verein 3-(Aminoacyl-amino)-saccharide und Verfahren zu ihrer Herstellung
AUPN862996A0 (en) * 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1020449A1 (fr) 1997-09-18 2000-07-19 Mitsubishi-Tokyo Pharmaceuticals, Inc. Composes d'imidazoline
FR2771093B1 (fr) 1997-11-19 2000-01-21 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
JP2003286266A (ja) 1999-03-24 2003-10-10 Mitsubishi-Tokyo Pharmaceuticals Inc イミダゾール化合物
CA2781858C (fr) * 2000-05-12 2015-03-31 Genzyme Corporation Modulateurs de marquage du tnf-.alpha.
WO2002004402A1 (fr) * 2000-07-11 2002-01-17 Banyu Pharmaceutical Co., Ltd. Derives d'ester
MXPA03002447A (es) * 2000-09-20 2003-07-21 Schering Corp Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina.
US20040092515A1 (en) * 2001-02-28 2004-05-13 Torbjjorn Lundstedt Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
CA2450579A1 (fr) * 2001-06-20 2003-01-03 Merck & Co., Inc. Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JPWO2003027060A1 (ja) 2001-09-20 2005-05-12 杏林製薬株式会社 ジフェニルブタンアミド誘導体
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
DE60226906D1 (de) 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
US6875774B2 (en) * 2002-08-06 2005-04-05 The University Of North Carolina Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands
US7410993B2 (en) 2002-08-09 2008-08-12 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
DE60231341D1 (de) * 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
WO2004056810A1 (fr) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques
EP1583741A1 (fr) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited Derives de 1-substitues-3-pyrrolidines comme antagonistes de recepteurs muscariniques
WO2004056811A1 (fr) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Derives de flavaxate comme antagonistes de recepteurs muscariniques
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004069835A1 (fr) 2003-02-07 2004-08-19 Ranbaxy Laboratories Limited Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
EP1595867A4 (fr) * 2003-02-10 2008-05-21 Banyu Pharma Co Ltd Antagonistes des recepteurs de l'hormone concentrant la melanine contenant des derives de piperidine en tant que principe actif
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
ATE362364T1 (de) 2003-04-10 2007-06-15 Ranbaxy Lab Ltd Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
CN100436414C (zh) * 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1781607A2 (fr) 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Derives de pyrrolidine utilises en tant qu'antagonistes des recepteurs muscariniques
EP1797040A1 (fr) 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Antagonistes de recepteurs muscariniques

Also Published As

Publication number Publication date
CA2635335A1 (fr) 2007-07-12
JP2009522246A (ja) 2009-06-11
EA200801591A1 (ru) 2008-12-30
US20100222393A1 (en) 2010-09-02
BRPI0620844A2 (pt) 2011-11-29
AU2006334107A1 (en) 2007-07-12
WO2007077510A3 (fr) 2007-11-01
WO2007077510A2 (fr) 2007-07-12
KR20080089461A (ko) 2008-10-06
EP1968945A2 (fr) 2008-09-17

Similar Documents

Publication Publication Date Title
HUS1400053I1 (hu) Muszkarin acetilkolin receptor antagonisták
EP1937068A4 (fr) Antagonistes de recepteurs d'acetylcholine muscarinique
EP1871752A4 (fr) Antagonistes du récepteur de l' orexine de type amidopropoxyphényle
HK1124831A1 (en) Histamine-3 receptor antagonists
IL187424A0 (en) C5a RECEPTOR ANTAGONISTS
IL176775A0 (en) Muscarinic acetylcholine receptor antagonists
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL190686A0 (en) Il-21 receptor antagonists
EP1749012A4 (fr) Antagonistes du recepteur d'acetylcholine muscarinique
EP1824483A4 (fr) Antagonistes des recepteurs de l'acetylcholine muscarinique
IL184278A0 (en) C5a RECEPTOR ANTAGONISTS
AP1983A (en) Carboxamide derivatives as muscarinic receptor antagonists
EP1725240A4 (fr) Antagonistes du recepteur d'acetylcholine muscarinique
EP1874302A4 (fr) Antagonistes des recepteurs de l'angiotensine ii
EP1765339A4 (fr) Antagonistes du recepteur muscarinique d'acetylcholine
EP1937267A4 (fr) Antagonistes des recepteurs de l' acetylcholine muscarinique m3
EP1937230A4 (fr) Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1781104A4 (fr) Antagonistes du recepteur d'acetylcholine muscarinique
EP1781103A4 (fr) Antagonistes du recepteur d'acetylcholine muscarinique
EP1898905A4 (fr) Antagonistes des recepteurs de tachykinine hydro-iso-indolique
AP2008004537A0 (en) Muscarinic receptor antagonists
GB0525029D0 (en) Receptor Antagonist
ZA200806223B (en) Muscarinic receptor antagonists
GB0516946D0 (en) Receptor
GB0516617D0 (en) EP2 Receptor antagonists